CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncolo...(certainties including uncertainties asso...)

Date:4/8/2008

certainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2007 fiscal year, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

'/>"/>

SOURCE Accuray Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
2. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
5. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
6. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
7. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound